TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02850692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measure of endothelial function
Description: Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measure of endothelial function
Description: Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.
Study: NCT03563170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: anhydrous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU; Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: NEXAVAR® tablets, for oral use
Study: NCT00950534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (HOE901)
Description: The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Anti Diabetics (OAD)
Description: Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
Study: NCT04069403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Reports on prescription patterns for their patients
Description: de-identified aggregate reports
Study: NCT01827657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
Study: NCT04044742

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receiving Placebo injection
Study: NCT04238507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guedel airway
Description: Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
Study: NCT01827657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
Study: NCT03225911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge insole (insole)
Description: The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
Study: NCT02850692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatic elastography
Description: Hepatic elastography by Fibrocan®. Patient should neither eat nor drink at least 2 hours before exam. 10 successive measurements are made.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injected abdominal CT
Description: Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit.
Study: NCT04238507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USASK airway
Description: Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
Study: NCT04200144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sleeve gastroplasty
Description: Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sleeve gastroplasty
Description: Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)
Study: NCT02420236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary rehabilitation program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program
Study: NCT01000324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Engerix-B will be administered to subjects who are not seroprotected against hepatitis B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
Study: NCT03801603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV vaccination training and education
Description: 1) Training of providers and clinic staff on the importance of providing a strong HPV vaccination program and 2) HPV vaccination education for parents and the community.
Study: NCT03455816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Social Diabetes App
Description: Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (glucomen Areo) allows through NFC technology the automatic introduction of data in the application

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical monitoring group (Control group)
Description: Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
Study: NCT04967027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASCLU-300 TTF
Description: BM treated by continuous TTFields treatment (ASCLU-300, approved by Chinese FDA)
Study: NCT02371408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir hydrochloride
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir hydrochloride
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir hydrochloride
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir hydrochloride
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir hydrochloride
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir hydrochloride
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 mg - 1200 mg per day, weight-based dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 mg - 1200 mg per day, weight-based dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 mg - 1200 mg per day, weight-based dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 mg - 1200 mg per day, weight-based dosing
Study: NCT01960517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACS Catheter
Study: NCT01454765

Intervention type: OTHER
Intervention: generation of stem cells
Description: Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
Study: NCT05063682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes
Description: ICV administration
Study: NCT04607811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification with social incentives
Description: Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
Study: NCT02567019

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Description: blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
Study: NCT00982839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Syringe Conditioning
Description: A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barostat Conditioning
Description: A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
Study: NCT02006979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
Study: NCT02850692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injected abdominal CT
Description: Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injected abdominal CT
Description: Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit.
Study: NCT04138381

Intervention type: DRUG
Group type: OTHER
Intervention: Selinexor
Description: oral selinexor given once weekly (Cohort A), oral selinexor given BIW (Cohort B)

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: imatinib 400 mg, once daily (Cohort A)
Study: NCT02561325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate and Sodium chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Bicarbonate and Sodium chloride
Study: NCT03774407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal estriol
Description: Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.

Intervention type: DRUG
Group type: OTHER
Intervention: vaginal estriol
Description: Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
Study: NCT03063411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Executive Function Intervention
Description: In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
Study: NCT01612065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 200 ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol vaginally, 400 ug
Study: NCT03684577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy for Agoraphobia
Description: see description of the experimental arm
Study: NCT03514108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine Isosorbide Dinitrate
Description: Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2 tablets x 3 daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
Study: NCT03225911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simple knee sleeve (sleeve)
Description: The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simple knee sleeve + lateral wedge insole
Description: The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
Study: NCT04537858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy first
Description: First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional therapy first
Description: First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
Study: NCT03410303

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Intraoperative ultrasound and 2 months post-operative ultrasound ( ± 1 month)
Description: An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
Study: NCT04224961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
Study: NCT02917395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
Study: NCT00634062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
Study: NCT04115137

Intervention type: DEVICE
Intervention: pelvic varicose veins plug embolization
Description: pelvic varicose veins plug embolization
Study: NCT00714311

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transference-Focused Psychotherapy
Description: Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment by experienced community psychotherapists
Description: Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
Study: NCT02221388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA, 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA, 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA EC, 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA EC, 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800 HEA, 50 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 671800 ED, 100 mg capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal
Study: NCT01609881

Intervention type: DRUG
Group type: OTHER
Intervention: Acuvail
Description: Dosing of drug 3 days prior to surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Artificial tears qid for 3 days preoperatively
Study: NCT02218008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT00106353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel
Description: 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
Study: NCT00406536

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lym-X-Sorb powder
Description: Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is \>99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
Study: NCT00588354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 200 or 400 micrograms clonidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: 40 or 80 milligrams triamcinolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl
Description: 1 ml 2% lidocaine (20 mg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine HCl
Description: 1 ml 2% lidocaine (20 mg/mL)